

## **Supplemental Material to:**

**Jiabo Di, Leon F.A.G. Massuger, Tjitske Duiveman-de Boer,  
Petra L.M. Zusterzeel, Carl G. Figdor and Ruurd Torensma**

**Functional Oct4-specific CD4+ and CD8+ T cells in healthy  
controls and ovarian cancer patients**

**Oncoimmunology 2013; 2(5)**

**<http://dx.doi.org/10.4161/onci.24271>**

**[http://www.landesbioscience.com/journals/oncoimmunology/  
article/24271/](http://www.landesbioscience.com/journals/oncoimmunology/article/24271/)**

**Supplementary Table 1**  
**CD4+ T cell stimulation by Oct4 peptide loaded DC**

Donor No.	IFN- $\gamma$	Proliferation
1	-(avg)	2/6
2	+(avg)	5/6
3	+(avg)	6/6
4	0/6	2/6
5	1/6	5/6
6	4/6	0/6
7	0/6	0/6
8	0/6	1/6
9	0/6	0/6
10	2/6	0/6
11	1/6	1/6
12	0/6	0/6

Avg: average of 6 wells  
e.g. 1/6 means one well was positive out of 6 wells

<b>Supplementary Table 2</b> <b>CD8+ T cell stimulation by Oct4 peptide loaded DC</b>		
Donor No.	IFN- $\gamma$	Proliferation
1	-(avg)	0/6
2	-(avg)	0/6
3	-(avg)	0/6
4	1/6	0/6
5	0/6	0/6
6	0/6	0/6
7	0/6	0/6
8	0/6	5/6
9	0/6	1/6
10	0/6	1/6
11	0/6	0/6
12	2/6	0/6
Avg: average of 6 wells e.g. 1/6 means one well was positive out of 6 wells		

<b>Supplementary Table 3</b> <b>Summary of patient information</b>			
Patient No.	Age	FIGO stage	Histological subtype
90	61	IIIc	Serous
98	76	IIIc	Serous
124	67	IIIc	Serous
130	60	IIIc	Serous
140	59	IV	Not defined